#Precigen to showcase rapid commercialization momentum and growing market adoption of first-and-only FDA-approved therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference.  View press release: bit.ly/jpm26-momentum #JPM26 #JPM2026

#Precigen to participate in upcoming virtual fireside chats hosted by Cantor and H.C. Wainwright to discuss the recent approval of the first and only FDA-approved therapy for the treatment of adults with RRP. View event details: bit.ly/41VSmMT

NIH is thrilled to announce that the @US_FDA has granted full market approval for Papzimeos, a groundbreaking immunotherapy for adult patients with recurrent respiratory papillomatosis (RRP), a rare condition in which noncancerous growths develop in the air passages from the nose and mouth into the lungs.🫁 This is the first-ever non-surgical treatment for this rare and debilitating disease. The achievement was made possible through the dedicated research of NIH investigators from @theNCI! 🔗 Read more about the approval: fda.gov/news-events/press-an…

Today, we approved a first-of-its-kind non-replicating adenoviral vector-based immunotherapy for the treatment of adult patients with recurrent respiratory papillomatosis. fda.gov/news-events/press-an…

#Precigen is proud to announce the first and only @US_FDA-approved therapy for the treatment of adults with #RecurrentRespiratoryPapillomatosis. View press release: bit.ly/papzimeos-FDAapproval

Join us on Wednesday, September 18 for a fireside chat with @Precigen's President and CEO, Helen Sabzevari, at the 2024 Cantor Global Healthcare Conference. View details and register for the webcast: bit.ly/3LqNK9i #CantorHCC

@Precigen reports second quarter / first half 2024 financial results and business updates. View press release and join our conference call today at 4:30pm ET: bit.ly/3yGJAae $PGEN

Join #Precigen on Wednesday, August 14, 2024 at 4:30 PM ET for a conference call to discuss second quarter and first half 2024 financial results. View details: bit.ly/3LqNK9i $PGEN

#ICYMI: Watch the replay and check out photos from the first #RRPAwarenessDay. Thank you to our patient and caregiver panelists, our co-hosts at RRPF, @theNCI panelists, @MarkWarner, @iamwesmoore and all who viewed the event! rrpawareness.org #GivingVoicetoInspireChange

We had an amazing time at our inaugural #RRPAwarenessDay. Together, we are shaping a hopeful and positive future for those impacted by RRP. Watch the #RRPAwarenessDay co-hosts share their thoughts on what they hope we achieved for RRP patients today. #GivingVoicetoInspireChange

Only 1 week to go until RRP Awareness Day, a multi-stakeholder event to raise awareness and bring together individuals living with RRP, caregivers, clinicians, and government officials. View details at rrpawareness.org and join us!

@Precigen is excited to announce pivotal study results for PRGN-2012 in RRP presented today in a late-breaking oral presentation at #ASCO24. Join us today for a live webcast with Precigen executives and study lead investigators. View data: bit.ly/3VqqRrV

#ASCO24: On Monday, June 3, check out the trial-in-progress poster for @Precigen's PRGN-2009 AdenoVerse Gene Therapy in recurrent or metastatic cervical cancer (Abstract # TPS5623). bit.ly/3VnqBKc #GeneTherapy #Oncology #ClinicalTrials #CervicalCancer #OncoAlert

#ASCO24: On Sunday, June 2, check out the trial-in-progress poster for @Precigen's PRGN-2009 AdenoVerse Gene Therapy in HPV-associated oropharyngeal cancer (Abstract# TPS6124). bit.ly/4bGwSXk #GeneTherapy #Oncology #ClinicalTrials #OncoAlert

#Precigen to host a webcast on June 3 at 6:00 PM CT following the late-breaking oral presentation of results from the pivotal study of PRGN-2012 for the treatment of RRP at #ASCO24. View details: bit.ly/3LqNK9i $PGEN